Our new immunotherapy book has been published by Springer:
http://www.springer.com/us/book/9783319298252
I want to take a moment to acknowledge the stunning group of authors who made the book a success. I’d also like to promote our fund raising effort in memory of Holbrook Kohrt, to whom the volume is dedicated – 5% of net sales will be donated by me, on behalf of all of our authors, the the Cancer Research Institute in New York. So please consider buying the book or just the chapters you want (they can be purchased individually through the link given above.
Now, the authors:
from Arlene Sharpe and her lab (Harvard Medical School, Boston):
Enhancing the Efficacy of Checkpoint Blockade Through Combination Therapies
from Taylor Schreiber (Pelican Therapeutics, Heat Biologics):
Parallel Costimulation of Effector and Regulatory T Cells by OX40, GITR, TNFRSF25, CD27, and CD137: Implications for Cancer Immunotherapy
from Russell Pachynski (Washington University St Louis) and Holbrook Kohrt (Stanford University Medical Center)
NK Cell Responses in Immunotherapy: Novel Targets and Applications
from Larry Kane and Greg Delgoffe (University of Pittsburgh School of Medicine):
Reversing T Cell Dysfunction for Tumor Immunotherapy
from Josh Brody and Linda Hammerich (Icahn School of Medicine, Mt Sinai, NYC)
Immunomodulation Within a Single Tumor Site to Induce Systemic Antitumor Immunity: In Situ Vaccination for Cancer
From Sheila Ranganath and AnhCo (Cokey) Nguyen (Enumeral Inc, Cambridge MA)
Novel Targets and Their Assessment for Cancer Treatment
From Thomas (TJ) Cradick, CRISPR Therapeutics, Cambridge MA):
Cellular Therapies: Gene Editing and Next-Gen CAR T Cells
From Chris Thanos (Halozyme Inc, San Diego) and myself:
The New Frontier of Antibody Drug Conjugates: Targets, Biology, Chemistry, Payload
and a second topic covered by Chris Thanos (Halozyme):
Targeting the Physicochemical, Cellular, and Immunosuppressive Properties of the Tumor Microenvironment by Depletion of Hyaluronan to Treat Cancer
and finally, my solo chapter (and representing Aleta Biotherapeutics, Natick MA and SugarCone Biotech, Holliston MA):
Novel Immunomodulatory Pathways in the Immunoglobulin Superfamily
Please spread the word that all sales benefit cancer research and more specifically, cancer clinical trial development and execution through the Cancer research Institute, and as I said, consider buying the book, or the chapters you want to read.
cheers-
Paul